CSL says low immunisation rates in the United States hurt first-half sales for its vaccination business but a solid result for its core blood plasma business meant it still expected to deliver double-digit earnings growth this year.
The pharmaceutical giant said on Tuesday first-half net profit rose 7 per cent to $US2.01 billion ($3.2 billion) after revenues lifted 5 per cent to $US8.48 billion. It declared an interim dividend of $US130 per share, up 9 per cent.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.